Revenue

Facing delisting, Hong Kong-based PTL Limited enacts a massive 1-for-80 share consolidation. But can this financial maneuver fix deeper business issues?

Tech giant OpenTable is shaking up London's dining scene with new awards, using its vast data, expert panels, and diner votes to crown the city's best.

New data on MCO-010 gene therapy identifies ideal patients for Retinitis Pigmentosa, a key step as the one-time injection advances toward FDA approval.

The partnership moves beyond compliance, integrating deep binary analysis with lifecycle management to provide continuous software risk intelligence for critical industries.

Target Hospitality is rapidly expanding workforce housing for AI data centers, revealing the massive, unseen physical infrastructure powering the tech revolution.

Penske Automotive's latest Florida acquisition highlights a fierce battle for the state's booming luxury car market, adding $450M in expected revenue.

Cullinan Therapeutics heads to key investor conferences, ready to showcase its T-cell engager platform for both cancer and challenging autoimmune diseases.

As Ring Energy preps its Q4 results, investors eye debt reduction, cost control, and 2026 strategy amid a challenging Permian market.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

Swiss biotech AC Immune begins a human trial for an oral drug aiming to halt the chronic inflammation driving diseases like Alzheimer's and Parkinson's.

Maiden drilling at West Santa Fe reveals significant near-surface gold, sparking speculation of a low-cost, open-pit mine in the prolific Walker Lane.

With no approved therapies for Hepatitis E, Atea Pharmaceuticals' new drug shows potent preclinical results, offering a potential lifeline for vulnerable patients.

Cell and gene therapy manufacturer OXB posts a dramatic turnaround to profitability, with surging revenues and an ambitious forecast for the coming years.

Blueprint Capital Advisors' new list of 'Active Icons' honors industry giants not just for wealth, but for their commitment to shaping a more inclusive future.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

The shipping and printing giant's spot on a top global list highlights a stable model for entrepreneurs and its vital role in supporting small businesses.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

A new report shows patients are rejecting 'overdone' looks for subtle, strategic care, driven by Ozempic, menopause, and a desire for authenticity.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.

Fintech firm Chronograph hires a private credit expert from Blue Owl and partners with AI leader Anthropic to revolutionize portfolio monitoring.